Gilteritinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Acute Myeloid Leukemia, Relapsed/Refractory Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also in development:Non-Small Cell Lung Cancer · Phase 1/2 · investigational in the US

Also approved (4)
CN
  • Conditional approval for relapsed or refractory AML with a FLT3 mutation
Product first approved 2021biospace.com
CA
  • Xospata® (gilteritinib tablets) is indicated for:  the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation. A validated test is required to confirm the FLT3 mutation status of AML.
Product first approved 2019Health Canada
EU
  • Monotherapy for adults with relapsed or refractory AML with a FLT3 mutation
Product first approved 2019EMA
JP
  • FLT3 mutation-positive relapsed or refractory acute myeloid leukemia (XOSPATA 40 mg tablets); first approval worldwide
Product first approved 20181stoncology.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (9)
Acute Myeloid Leukemia
NCT04027309 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2019-12-20 – 2033-06 · Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
What this study did
NCT07407140 · Institute of Hematology & Blood Diseases Hospital, China
2026-04-30 – 2030-12-31 · AML, Adult
What this study did
NCT07463651 · The First Affiliated Hospital of Soochow University
2026-05-01 – 2030-03-31 · Acute Myeloid Leukemia (AML), FLT3-ITD Mutation, Allogeneic Hematopoietic Cell Transplantation (HCT), Maintenance Therapy, Gilteritinib, Sorafenib
What this study did
NCT04293562 · Children's Oncology Group
2020-07-21 – 2029-06-30 · Acute Myeloid Leukemia
What this study did
NCT05177731 · Chen Suning
2022-03-01 – 2024-12-31 · AML, Adult, Chemotherapy Effect
What this study did
Relapsed/Refractory Acute Myeloid Leukemia
NCT03182244 · Astellas Pharma Inc
2017-10-25 – 2026-07-29 · AML With FLT3 Mutation
What this study did
Phase 2/3 (2)
Acute Myeloid Leukemia
NCT07425808 · European Organisation for Research and Treatment of Cancer - EORTC
2026-12-01 – 2032-02-01 · AML (Acute Myeloid Leukemia)
What this study did
Relapsed/Refractory Acute Myeloid Leukemia
NCT03013998 · Beat AML, LLC
2016-11 – 2032-12 · Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
What this study did
Phase 2 (16)
Acute Myeloid Leukemia
NCT05955261 · St. Jude Children's Research Hospital
2023-07-25 – 2034-03 · Acute Myeloid Leukemia
What this study did
NCT06667973 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2025-06 – 2030-06 · Acute Myeloid Leukemia, FLT3 Gene Mutation, Adult AML, Diagnosis
What this study did
NCT07755202 · Florian Kuchenbauer
2026-09-01 – 2030-05-01 · Acute Myeloid Leukemia, AML With FLT3 Mutation
What this study did
NCT06696183 · Technische Universität Dresden
2025-04-25 – 2030-04 · AML - Acute Myeloid Leukemia
What this study did
NCT07259707 · First Affiliated Hospital of Zhejiang University
2026-01-25 – 2029-12-31 · Acute Myeloid Leukemia, FLT3 Internal Tandem Duplication Positive, Intermediate Risk Acute Myeloid Leukemia, Fit Patients
What this study did
NCT06221683 · Children's Hospital of Soochow University
2024-01-01 – 2029-12 · AML, Childhood, Acute Myeloid Leukemia
What this study did
NCT05564390 · National Cancer Institute (NCI)
2024-06-18 – 2029-05-15 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
What this study did
NCT06317649 · National Cancer Institute (NCI)
2024-09-27 – 2029-05-15 · Acute Myeloid Leukemia
What this study did
NCT07548710 · Ruijin Hospital
2026-05-01 – 2028-12-21 · Acute Myeloid Leukemia
What this study did
NCT05199051 · Centre Antoine Lacassagne
2023-06-03 – 2028-07-10 · AML, Leukaemia (Acute Myeloid)
What this study did
NCT06022003 · French Innovative Leukemia Organisation
2024-01-13 – 2027-10 · AML, Adult, Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation, FLT3-ITD
What this study did
NCT03836209 · PrECOG, LLC.
2019-12-06 – 2026-06-30 · Acute Myeloid Leukemia
What this study did
NCT02927262 · Astellas Pharma Global Development, Inc.
2017-01-10 – 2024-02-19 · Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation
What this study did
Relapsed/Refractory Acute Myeloid Leukemia
NCT07949370 · Dana-Farber Cancer Institute
2027-03-06 – 2030-07-31 · Relapsed or Refractory Acute Myeloid Leukemia (AML)
What this study did
NCT02115295 · M.D. Anderson Cancer Center
2014-05-19 – 2030-05-31 · Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, Blasts 10 Percent or More of Peripheral Blood White Cells, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
What this study did
Other / comorbidity
NCT07032727 · M.D. Anderson Cancer Center
2025-09-12 – 2029-06-01 · Targeted Therapy, IDH1-Mutated Malignancies, Mutations
What this study did
Phase 1/2 (14)
Acute Myeloid Leukemia
NCT06235801 · M.D. Anderson Cancer Center
2024-05-22 – 2029-10-01 · Myeloid Leukemia
What this study did
NCT05520567 · Astellas Pharma Global Development, Inc.
2023-01-31 – 2028-07-31 · Acute Myeloid Leukemia (AML), FLT3-mutated Acute Myeloid Leukemia
What this study did
NCT04988555 · Sumitomo Pharma America, Inc.
2022-02-28 – 2027-12-31 · Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
What this study did
NCT06561880 · Institute of Hematology & Blood Diseases Hospital, China
2024-10-08 – 2027-08-31 · FLT3 Gene Mutation, AML
What this study did
NCT05279859 · Erasca, Inc.
2022-03-15 – 2025-06-01 · Acute Myeloid Leukemia
What this study did
NCT02310321 · Astellas Pharma Inc
2015-02-26 – 2024-07-09 · Acute Myeloid Leukemia, FLT3-mutated Acute Myeloid Leukemia
What this study did
NCT03730012 · Astellas Pharma Global Development, Inc.
2019-06-19 – 2021-06-15 · Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
What this study did
NCT02561455 · Astellas Pharma Global Development, Inc.
2016-05-03 – 2020-07-28 · Advanced Solid Tumors, Acute Myeloid Leukemia
What this study did
Non-Small Cell Lung Cancer
Relapsed/Refractory Acute Myeloid Leukemia
NCT04140487 · M.D. Anderson Cancer Center
2019-12-17 – 2028-09-01 · Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm
What this study did
NCT05010122 · M.D. Anderson Cancer Center
2021-07-08 – 2028-01-30 · Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT04240002 · Astellas Pharma Global Development, Inc.
2020-09-04 – 2025-03-17 · Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase 3 (FLT3) Mutation / Internal Tandem Duplication (ITD)
What this study did
NCT05028751 · Kronos Bio
2022-08-05 – 2024-04-09 · Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT02014558 · Astellas Pharma Global Development, Inc.
2013-10-09 – 2018-03-07 · Acute Myeloid Leukemia
What this study did
Phase 1 (18)
Acute Myeloid Leukemia
NCT05330377 · Ayman H Qasrawi
2023-03 – 2032-05-30 · Acute Myeloid Leukemia
What this study did
NCT05756777 · Memorial Sloan Kettering Cancer Center
2023-10-25 – 2027-04-21 · Acute Myeloid Leukemia (AML)
What this study did
NCT05024552 · H. Lee Moffitt Cancer Center and Research Institute
2022-02-25 – 2027-03 · Acute Myeloid Leukemia With FLT3/ITD Mutation
What this study did
NCT05010772 · M.D. Anderson Cancer Center
2021-10-25 – 2026-12-31 · Acute Myeloid Leukemia
What this study did
NCT04336982 · Celgene
2020-08-05 – 2024-04-05 · Leukemia, Myeloid, Acute
What this study did
NCT02236013 · Astellas Pharma Global Development, Inc.
2015-01-07 – 2021-07-26 · Acute Myeloid Leukemia
What this study did
Non-Small Cell Lung Cancer
NCT07140016 · Astellas Pharma Global Development, Inc.
2025-09-22 – 2029-12-31 · Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
What this study did
NCT06225427 · University of Michigan Rogel Cancer Center
2024-07-25 – 2027-05 · Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
What this study did
Relapsed/Refractory Acute Myeloid Leukemia
NCT06001788 · Kura Oncology, Inc.
2024-02-22 – 2027-08 · AML, AML With Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
What this study did
NCT06222580 · Uma Borate
2024-02-20 – 2027-02-28 · Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT05546580 · Oryzon Genomics S.A.
2022-11-14 – 2026-12-05 · Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
What this study did
NCT04655391 · City of Hope Medical Center
2022-06-25 – 2023-12-15 · Recurrent Acute Myeloid Leukemia
What this study did
NCT03625505 · AbbVie
2018-10-18 – 2021-08-31 · Acute Myeloid Leukemia (AML)
What this study did
NCT02181660 · Astellas Pharma Inc
2014-06-16 – 2016-06-27 · Acute Myeloid Leukemia (AML)
What this study did
Other / comorbidity
NCT04699877 · Astellas Pharma Global Development, Inc.
2021-01-28 – 2022-07-18 · Renal Impaired, Gilteritinib, Normal Renal Function, Pharmacokinetics of ASP2215
What this study did
NCT02456883 · Astellas Pharma Global Development, Inc.
2016-03-04 – 2017-06-19 · Advanced Solid Tumors, Pharmacokinetics of 14C-labeled Gilteritinib
What this study did
NCT02571816 · Astellas Pharma Global Development, Inc.
2015-10-23 – 2016-03-05 · Hepatic Impairment, Healthy
What this study did
Early phase / not applicable (3)
Acute Myeloid Leukemia
NCT07131059 · Institute of Hematology & Blood Diseases Hospital, China
2024-05-11 – 2028-10-30 · AML, Adult
What this study did
NCT06265545 · Institute of Hematology & Blood Diseases Hospital, China
2024-02-22 – 2028-06-30 · AML, Refractory, Relapsed
What this study did
Other / comorbidity
NCT06992934 · Centre Hospitalier Universitaire de Nice
2026-09 – 2028-08 · Hematological Malignancies
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Gilteritinib: this drugApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
Azacitidine (Onureg)ApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
Gemtuzumab OzogamicinApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)ApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
QuizartinibApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Sargramostim (Leukine)ApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
Tretinoin (Vesanoid)
ApprovedUS marketing discontinued
Small moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
VenetoclaxApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
VyxeosApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
AzacitidinePhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
Sonrotoclax (Beqalzi)Phase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
TagraxofuspPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race
OlverembatinibPhase 1/2Small moleculeBCR-ABL (also AKT, c-Kit, ERK)not yet gradedNo reviewed efficacy summary in this indication
OrcaGraft (Orca-Q)Phase 1/2Cell therapyTreg-enriched allogeneic haematopoietic stem cell graftnot yet gradedNo reviewed efficacy summary in this indication
RogocekibPhase 1/2Small moleculeCLK (CDC-like kinase family)not yet gradedNo reviewed efficacy summary in this indication
Anti-CI135 CAR-TPhase 1Cell therapyFLT3not yet gradedNo reviewed efficacy summary in this indication
PRGN-3006Phase 1Cell therapyCD33Weak signal
NCT03927261: PRGN-3006 (NCT03927261): no dose-limiting toxicities (DLTs) observed.
BMF-500Discontinued—FLT3not yet gradedNo reviewed efficacy summary in this indication
CamibirstatDiscontinuedSmall moleculeSMARCA4/SMARCA2 (BRG1/BRM ATPase subunits)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 67 furthest-along competitors are listed; 63 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(33 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Gilteritinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12 · NCT06001788 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12 · NCT05955261 · CT.gov ↗
What to watch
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT05010772 · CT.gov ↗
What to watch
2027 (8)
January 2027 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-01-31 · NCT06222580 · CT.gov ↗
What to watch
February 2027 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-02-15 · NCT05024552 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-04-21 · NCT05756777 · CT.gov ↗
What to watch
May 2027 (2)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05 · NCT06225427 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-05-31 · NCT07548710 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2Targeted Therapy, IDH1-Mutated Malignancies, MutationsRecruiting
Est. primary completion 2027-06-01 · NCT07032727 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-06-30 · NCT04988555 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-10-01 · NCT06235801 · CT.gov ↗
What to watch
2028 (12)
January 2028 (2)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01-30 · NCT05010122 · CT.gov ↗
What to watch
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2028-01-30 · NCT06265545 · CT.gov ↗
What to watch
May 2028 (2)
Early phase / not applicableAcute Myeloid LeukemiaRecruiting
Est. primary completion 2028-05-10 · NCT07131059 · CT.gov ↗
What to watch
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-05-31 · NCT07463651 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-07-10 · NCT05199051 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-07-31 · NCT05520567 · CT.gov ↗
What to watch
August 2028 (2)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-08 · NCT06667973 · CT.gov ↗
What to watch
Early phase / not applicableHematological MalignanciesNot yet recruiting
Est. primary completion 2028-08 · NCT06992934 · CT.gov ↗
What to watch
September 2028 (1)
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-09-01 · NCT04140487 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2/3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2028-10-01 · NCT07425808 · CT.gov ↗
What to watch
December 2028 (2)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12 · NCT06221683 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT07259707 · CT.gov ↗
What to watch
2029 (8)
February 2029 (1)
Phase 3Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-02-01 · NCT07407140 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-04 · NCT06696183 · CT.gov ↗
What to watch
May 2029 (2)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-05-15 · NCT05564390 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-05-15 · NCT06317649 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-06-30 · NCT04293562 · CT.gov ↗
What to watch
October 2029 (1)
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-10-01 · NCT07755202 · CT.gov ↗
What to watch
December 2029 (2)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2029-12-31 · NCT07140016 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-12-31 · NCT07949370 · CT.gov ↗
What to watch
2030 (1)
May 2030 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2030-05-31 · NCT02115295 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
Phase 2/3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2032-12 · NCT03013998 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 March 2026Topline resultPhase 3 HOVON 156 / AMLSG 28-18 / PASHA (NCT04027309) missed its overall survival primary endpoint
Astellas Pharma Inc. and HOVON · Source ↗